None listed
Conditions
Brief summary
COPD is an incurable disease with high morbidity and mortality rates, due to hospitalisations from the condition and antibiotic-resistant respiratory infections. Zinc deficiency could increase the risk of recurrent airway infections. Incorporating zinc therapy into COPD treatment could be a significant breakthrough, particularly in light of our previous findings of low zinc levels in the airways of COPD patients.
Interventions
Zinc gluconate, 30 mg, will be administered as a daily oral tablet for 12 months. To monitor adherence, participants will receive a bottle each month, and the remaining tablets will be counted at each visit to assess their compliance with the treatment regimen.
Sponsors
University of Adelaide
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
45 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
COPD patients who are over 45 years of age and have a past history of at least 2 exacerbations per year for the last 2 years with no respiratory infection for 6 weeks prior.
Exclusion criteria
Patients with other respiratory conditions, such as asthma, bronchiectasis, pulmonary fibrosis, or lung cancer and Patients with concomitant diseases where it is not in the patient’s medical interest to receive zinc supplements.
Outcome results
None listed